We are live on ! Find out more
RYTM icon

Rhythm Pharmaceuticals
RYTM

279 hedge funds and large institutions have $7.8B invested in Rhythm Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 57 funds opening new positions, 106 increasing their positions, 89 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more first-time investments, than exits

New positions opened: 57 | Existing positions closed: 40

41% more call options, than puts

Call options by funds: $45.9M | Put options by funds: $32.5M

19% more repeat investments, than reductions

Existing positions increased: 106 | Existing positions reduced: 89

8% more capital invested

Capital invested by funds: $7.2B → $7.8B (+$598M)

6% more funds holding

Funds holding: 264 → 279 (+15)

2.45% more ownership

Funds ownership: 106.73% → 109.17% (+2.4%)

0% more funds holding in top 10

Funds holding in top 10: 10 → 10 (0)

Holders
279
Holders Change
+15
Holders Change %
+5.68%
% of All Funds
3.39%
Holding in Top 10
10
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.12%
New
57
Increased
106
Reduced
89
Closed
40
Calls
$45.9M
Puts
$32.5M
Net Calls
+$13.5M
Net Calls Change
-$21.7M

Top Buyers

1
Vanguard Group
Vanguard Group
Pennsylvania
+$129M
2
RCM
RA Capital Management
Massachusetts
+$105M
3
Jennison Associates
Jennison Associates
New York
+$53.8M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$45.6M
5
Capital Research Global Investors
Capital Research Global Investors
California
+$41M

Top Sellers

1
Alkeon Capital Management
Alkeon Capital Management
New York
-$103M
2
Primecap Management
Primecap Management
California
-$83.2M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$46.6M
4
Voloridge Investment Management
Voloridge Investment Management
Florida
-$32.6M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$29.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bessemer Group
251
Bessemer Group
New Jersey
$7K – – –
WA
252
WPG Advisers
Maryland
$6.42K +$318 +3 +5%
HI
253
Harbour Investments
Wisconsin
$6.42K +$6.37K +60 New
EB
254
Eastern Bank
Massachusetts
$6.32K +$6.26K +59 New
RFP
255
Root Financial Partners
California
$4.6K +$4.56K +43 New
OP
256
ORG Partners
Indiana
$3.96K +$530 +5 +16%
VCM
257
Versant Capital Management
Arizona
$3.85K – – –
IA
258
IFP Advisors
Florida
$3.85K +$1.8K +17 +89%
PFBT
259
Parkside Financial Bank & Trust
Missouri
$3.53K – – –
SAG
260
SageView Advisory Group
California
$3.21K +$3.18K +30 New
FHC
261
First Horizon Corporation
Tennessee
$3.21K +$3.18K +30 New
PA
262
Parallel Advisors
California
$2.68K – – –
BFS
263
Bare Financial Services
Pennsylvania
$2.35K +$424 +4 +22%
PWA
264
Physician Wealth Advisors
Utah
$1.71K – – –
RS
265
Rakuten Securities
Japan
$1.61K +$1.59K +15 New
CFO
266
CVA Family Office
Colorado
$1.28K – – –
JWA
267
JFS Wealth Advisors
Pennsylvania
$1.07K +$1.06K +10 New
KFAS
268
Keating Financial Advisory Services
Kansas
$963 +$955 +9 New
FFO
269
Fortitude Family Office
Arizona
$642 +$636 +6 New
Toronto Dominion Bank
270
Toronto Dominion Bank
Ontario, Canada
$642 +$636 +6 New
DPW
271
DiNuzzo Private Wealth
Pennsylvania
$322 +$318 +3 New
MCM
272
MAI Capital Management
Ohio
$215 -$197K -1,855 -100%
HIA
273
HFM Investment Advisors
New Jersey
$215 +$212 +2 New
SIC
274
SJS Investment Consulting
Ohio
$215 +$212 +2 New
RWM
275
Rialto Wealth Management
New York
$108 +$106 +1 New
9 10
11
12 13

RYTM Hedge Fund Activity: Q4 2025 in Review

279 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q4 2025, worth a combined $7.8B — up 8.3% from $7.2B a quarter earlier.

Buyers outnumbered sellers: 57 funds opened new RYTM positions and 40 closed out — a net gain of 17 holders — while 106 added to existing stakes and 89 trimmed.

The largest buyer was Vanguard Group, adding an estimated $129M. The largest seller was Alkeon Capital Management, exiting entirely with an estimated $103M sold.

  • 279 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q4 2025, up from 264 in Q3 2025.
  • Funds reported $7.8B of Rhythm Pharmaceuticals stock for Q4 2025, up 8.3% quarter-over-quarter.
  • 57 funds opened new Rhythm Pharmaceuticals positions in Q4 2025 and 40 closed out, a net change of +17 holders.
  • The largest Rhythm Pharmaceuticals buyer in Q4 2025 was Vanguard Group, an estimated $129M added.
  • The largest Rhythm Pharmaceuticals seller in Q4 2025 was Alkeon Capital Management, an estimated $103M sold.

Based on aggregated 13F filings for Q4 2025.